DRUG
Tirzepatide
Administered SC
Status
Completed
Phase
Phase 4
Enrollment
282
Locations
38
Results
Posted
Publications
2
Study summary
The main purpose of this study is to investigate the efficacy and safety of switching from weekly dulaglutide to weekly tirzepatide compared to increasing the dulaglutide dose in adults with type 2 diabetes.
Interventions
DRUG
Administered SC
DRUG
Administered SC
Timeline
First posted
Oct 3, 2022
Study start
Nov 30, 2022
Primary completion
Jul 15, 2024
Study completion
Aug 12, 2024
Results posted
Aug 3, 2025
Registry updated
Aug 3, 2025
Outcomes
Change From Baseline in HbA1c
Time frame · Baseline, Week 40
HbA1c is the glycated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least squares (LS) mean was calculated using mixed model repeated measures (MMRM) for post-baseline measures: Variable = Baseline + Number of Background OAMs Group 1 + Dulaglutide Dose at Screening + Geographic Region 1 + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.
Change From Baseline in Body Weight
Time frame · Baseline, Week 40
LSMean was calculated using MMRM for post-baseline measures: Variable = Baseline + Number of Background OAMs Group 1 + Dulaglutide Dose at Screening + Geographic Region 1 + Baseline HbA1c Group + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.
Percentage of Participants Who Achieved HbA1c <7%
Time frame · Week 40
The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable. Missing endpoint measures are imputed by predictions from an MMRM analysis model using observed data in the efficacy analysis set and adjusted for Baseline HbA1c Value, Baseline SGLT2i use(Yes/No), Treatment, Visit, and Treatment by Visit interaction.
Percentage of Participants Who Achieved HbA1c <=6.5%
Time frame · Week 40
The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable. Logistic regression model was used with missing endpoint measures imputed by predictions from an MMRM analysis model using observed data in the efficacy analysis set and adjusted for baseline HbA1c, geographic region 1, number of background OAMs in group 1, dulaglutide dose at screening, and treatment as factors.
Percentage of Participants Who Achieved HbA1c <5.7%
Time frame · Week 40
The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable. Logistic regression model was used with missing endpoint measures imputed by predictions from an MMRM analysis model using observed data in the efficacy analysis set and adjusted for baseline HbA1c, geographic region 1, number of background OAMs in group 1, dulaglutide dose at screening, and treatment as factors.
Percentage of Participants Who Achieve Weight Loss From Baseline of ≥5%
Time frame · Week 40
Missing endpoint measures are imputed by predictions using observed data in the efficacy analysis set from the same treatment group through an MMRM analysis model for post-baseline measures: Variable = Baseline + Geographic Region 1 + Number of Background OAMs Group 1 + Dulaglutide Dose at Screening + Baseline HBA1C Group + Treatment + Time + Treatment\*Time.
Percentage of Participants Who Achieve Weight Loss From Baseline of ≥10%
Time frame · Week 40
Missing endpoint measures are imputed by predictions using observed data in the efficacy analysis set from the same treatment group through an MMRM analysis model for post-baseline measures: Variable = Baseline + Geographic Region 1 + Number of Background OAMs Group 1 + Dulaglutide Dose at Screening + Baseline HBA1C Group + Treatment + Time + Treatment\*Time.
Percentage of Participants Who Achieve Weight Loss From Baseline of ≥15%
Time frame · Week 40
Missing endpoint measures are imputed by predictions using observed data in the efficacy analysis set from the same treatment group through an MMRM analysis model for post-baseline measures: Variable = Baseline + Geographic Region 1 + Number of Background OAMs Group 1 + Dulaglutide Dose at Screening + Baseline HBA1C Group + Treatment + Time + Treatment\*Time.
Percentage of Participants Who Achieved Composite Endpoint (HbA1c <=6.5% & Weight Loss >=10% & No-Hypoglycemia)
Time frame · Week 40
A composite endpoint is defined as HbA1c ≤ 6.5%, weight loss ≥ 10%, and no hypoglycemia, defined as blood glucose (BG) \<3.0 millimole/liter (mmol/L) and/or severe hypoglycemia. Missing endpoint measures are imputed by predictions using observed data in the efficacy analysis set from the same treatment group through an MMRM analysis model for post-baseline measures: For HbA1c: Variable = Baseline + Geographic Region 1 + Number of Background OAMs Group 1 + Dulaglutide Dose at Screening + Treatment + Time + Treatment\*Time. For Weight: Variable = Baseline + Geographic Region 1 + Number of Background OAMs Group 1 + Dulaglutide Dose at Screening + Baseline HbA1c Group + Treatment + Time + Treatment\*Time.
Change From Baseline in Fasting Serum Glucose (FSG)
Time frame · Baseline, Week 40
LSMean was calculated using the ANCOVA model for endpoint measures: Variable = Baseline + A1CGR1 + DULDSCRN + OAMGR1 + REGION1 + Treatment (Type I sum of squares).
Change From Baseline in Waist Circumference
Time frame · Baseline, Week 40
LSMean was calculated using MMRM for post-baseline measures: Variable = Baseline + Number of Background OAMs Group 1 + Dulaglutide Dose at Screening + Geographic Region 1 + Baseline HbA1c Group + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.
Eligibility
Inclusion Criteria: * Have type 2 diabetes * Have HbA1c ≥7.0% (≥53 mmol/mol) to ≤9.5% (≤80 mmol/mol) * Are currently on a stable dose of dulaglutide weekly (0.75 mg or 1.5 mg) for at least 6 months prior to screening. * No treatment with oral antihyperglycemic medication (OAM), or on a stable dose of up to 3 OAMs, which may include metformin, sodium glucose cotransporter-2 inhibitors (SGLT-2i), and/or sulfonylurea, for at least 3 months before screening. * Have had stable body weight (±5%) during the 90 days preceding screening * Have BMI ≥25 kilogram/square meter (kg/m²) Exclusion Criteria: * Have type 1 diabetes * Have a history of chronic or acute pancreatitis * Have a history of * proliferative diabetic retinopathy, or * diabetic maculopathy, or * nonproliferative diabetic retinopathy that requires acute treatment. * Have any of these cardiovascular (CV) conditions within 60 days prior to screening: * acute myocardial infarction, * cerebrovascular accident (stroke), or * hospitalization due to congestive heart failure (CHF). * Have New York Heart Assocation (NYHA) Functional Classification Class IV CHF * Have family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2). * Have within 90 days prior to screening received treatment with medications intended to promote weight loss. This includes prescribed, over-the-counter, or alternative remedies * Have an estimated glomerular filtration rate (eGFR) \<30 mL/minute/1.73 m2 (or lower than the country-specific threshold for discontinuing metformin therapy per local label) * Have been treated with insulin prior to screening * Exception: use of insulin for gestational diabetes or short-term use (\<14 days) for acute conditions such as acute illness, hospitalization, or elective surgery. * Have a history of reduction of dose of dulaglutide, due to intolerability, without successful reescalation
Study locations
Belgium · Germany · Mexico · Romania · United States. Showing up to 24 locations stored in the fast local snapshot.
ALL Medical Research, LLC
Cooper City, Florida, United States
Metabolic Research Institute, Inc.
West Palm Beach, Florida, United States
NorthShore University Health System
Skokie, Illinois, United States
Iowa Diabetes and Endocrinology Research Center
West Des Moines, Iowa, United States
Clinvest Research LLC
Springfield, Missouri, United States
Alliance for Multispecialty Research, LLC
Norman, Oklahoma, United States
Juno Research
Houston, Texas, United States
Biopharma Informatic, LLC
Houston, Texas, United States
Juno Research
Houston, Texas, United States
Southern Endocrinology Associates
Mesquite, Texas, United States
North Hills Family Medicine/North Hills Medical Research
North Richland Hills, Texas, United States
Imelda General Hospital
Bonheiden, Antwerpen, Belgium
Antwerp University Hospital
Edegem, Antwerpen, Belgium
ZNA Jan Palfijn
Merksem, Flanders, Belgium
AZ Nikolaas
Sint-Niklaas, Oost-Vlaanderen, Belgium
UZ Leuven
Leuven, Vlaams-Brabant, Belgium
Az Damiaan vzw
Ostend, West-Vlaanderen, Belgium
InnoDiab Forschung Gmbh
Essen, North Rhine-Westphalia, Germany
Institut für Diabetesforschung GmbH Münster
Münster, North Rhine-Westphalia, Germany
Studienzentrum Dr. Tasso Bieler
Riesa, Saxony, Germany
RED-Institut GmbH
Oldenburg in Holstein, Schleswig-Holstein, Germany
Medizinisches Versorgungszentrum am Bahnhof Spandau
Spandau, State of Berlin, Germany
Diabeteszentrum Hamburg West
Hamburg, Germany
Diseno y Planeacion en Investigacion Medica
Guadalajara, Jalisco, Mexico
Publications
Related trials
Ohio State University · Obesity & Overweight · Diabetes (DM)
Not applicable
Recruiting
300
2026-07
Eli Lilly · Type 2 Diabetes
Phase 3
Recruiting
55
2026-07
Eli Lilly · Diabetes Mellitus, Type 2
Phase 3
Not yet recruiting
170
2026-07
Brigham and Women's Hospital · Type 2 Diabetes
Not applicable
Completed
300,000
2026-07
Brigham and Women's Hospital · Type 2 Diabetes · Overweight
Not applicable
Completed
60,000
2026-07
Brigham and Women's Hospital · Type 2 Diabetes Mellitus · Obesity
Not applicable
Completed
120,000
2026-07
Eli Lilly · Type 2 Diabetes Mellitus
Phase 3
Completed
13,299
2026-07
ProGen. Co., Ltd. · Type 2 Diabetes
Phase 2
Not yet recruiting
60
2026-07
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.